Article Download
Benefits of ddPCR™ Technology in Mycoplasma Detection
Mycoplasma contamination of cell lines and downstream processes are difficult to detect and eradicate if present in the final product. Regulatory agencies have developed strict requirements to ensure drugs remain Mycoplasma-free. Traditional approaches to detecting Mycoplasma, however, are slow and insensitive, and often drug developers lose cell lines and production time despite their best efforts. Many are therefore turning to ddPCR™ technology, a rapid, sensitive, specific, and scalable method for detecting Mycoplasma contamination.
Read this article to learn:
- Why master and working cell banks, growth media, bioreactor unprocessed bulk, and purified and final product must all be tested for Mycoplasma contamination
- Why traditional methods such as agar and broth cultures, staining, ELISA, and even RT-PCR are limited in their ability to reliably detect Mycoplasma
- Why ddPCR technology is a reliable, sensitive, and rapid approach for detecting Mycoplasma contamination and ensuring the safety of the drugs that reach patients
Download the Article
Share a little information with us to access the entire article now.
Content you'll also find interesting
Recommended Features
-
Image
Using Droplet Digital™ PCR to Detect Mycoplasma Contamination
Learn how traditional methods for detecting Mycoplasma fall short, the challenges associated, and how ddPCR technology can improve contamination detection.
-
Image
Switching from qPCR to ddPCR™ Technology for Impurities Testing
Find out how switching from qPCR to ddPCR technology for contamination detection can ensure antibody therapeutic safety, potency, and consistency.
-
Image
Biosimilar Production with IEX and Mixed-Mode Resins
Learn how process economics is improved more than fourfold for biosimilar production with an ion exchange and mixed-mode purification workflow.
